文献速递腹部技术与安全US

准确NAFLD超声分级的临床效用:一项基于社区的前瞻性队列研究结果

The clinical utility of accurate NAFLD ultrasound grading: Results from a community-based, prospective cohort study.
PubMed 文献 · Eur J Radiol · 2021-01-02

该前瞻性社区队列研究在2007年纳入2985人、2014年随访2148人,比较仅肝回声增高(中度NAFLD)与附加信号衰减和/或血管模糊标准(中重度NAFLD)对不良代谢特征及心血管事件的预测价值。结果仅中重度NAFLD与随访7年后新发不良代谢特征和心血管事件风险显著相关,但两种分级均与基线不良代谢特征高患病率相关。作者据此推荐使用肝回声增高、而非仅用更严格标准来诊断NAFLD。

要点

  • 仅肝回声增高即可识别基线不良代谢特征高患病者,包括轻度脂肪肝人群。
  • 附加信号衰减和/或血管模糊的中重度NAFLD可预测7年后新发代谢异常和心血管事件。
  • 作者推荐使用肝回声增高而非仅用更严格标准诊断NAFLD。

核心结论

  • 仅中重度NAFLD可预测随访期间新发不良代谢特征和心血管事件风险。
  • 中重度和中度NAFLD均与基线不良体格测量指标和代谢特征患病率较高相关,可识别包括轻度脂肪肝在内需医疗干预的个体。
  • 作者推荐使用肝回声增高、而非仅用更严格标准(含信号衰减和/或血管模糊)诊断NAFLD。

研究设计与样本

  • 研究为正在进行的社区前瞻性队列研究,2007年初步筛查、2014年通过访谈、体格测量、肝脏超声和血液检查复评。
  • 2007年招募2985人,其中940人(31.5%)为中重度NAFLD、595人(19.9%)为中度NAFLD、957人(32.1%)为对照(无脂肪肝)。
  • 2014年随访2148人(71.9%),基线时包括708例中重度NAFLD、446例中度NAFLD和674例对照。
  • 超声分级标准:仅肝回声增高定义为中度NAFLD;肝回声增高附加信号衰减和/或血管模糊定义为中重度NAFLD。

关键影像表现/征象

  • 中重度NAFLD表现为肝回声增高并伴信号衰减和/或血管模糊。
  • 中度NAFLD仅表现为肝回声增高,不伴信号衰减或血管模糊。

诊断标准与关键数值

  • 中度NAFLD的超声标准为仅肝回声增高。
  • 中重度NAFLD的超声标准为肝回声增高加上信号衰减和/或血管模糊。

临床应用与阅片要点

  • 作者推荐在NAFLD个体中使用肝回声增高、而非仅用更严格标准(含信号衰减和/或血管模糊)诊断脂肪肝。
  • 仅肝回声增高即可识别基线不良代谢特征高患病者,即使轻度脂肪肝也需医疗干预。
  • 中重度NAFLD与随访7年后新发不良代谢特征和心血管事件风险显著相关,可用于风险分层。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVES: Despite its widespread use there is no consensus on ultrasound criteria to diagnose fatty liver.

METHOD: In an ongoing, cohort-study, participants were initially screened in 2007 and reassessed in 2014 by interview, anthropometric measurements, liver ultrasonography, and blood tests. We evaluated utility of increased hepatic echogenicity alone (intermediate) compared to using additional criteria which included signal attenuation and/or vascular blunting along with increase of hepatic echogenicity (moderate-severe), to diagnose fatty liver in NAFLD. We made a comparison of the two radiologically defined groups, in order to choose a classification method for NAFLD, which may better predict baseline adverse metabolic traits (MT), and adverse metabolic and cardiovascular events (CVE) after 7-year of follow-up.

RESULTS: Of 2985 recruited in 2007, 940 (31.5 %) had moderate-severe NAFLD, 595 (19.9 %) intermediate NAFLD, and 957 (32.1 %) were controls (no fatty liver). 2148 (71.9 %) attended follow-up in 2014; they included 708 who had moderate-severe NAFLD, 446 intermediate NAFLD and 674 controls, at baseline (in 2007). At baseline, adverse anthropometric indices and MTs were significantly higher in both moderate-severe NAFLD and intermediate NAFLD compared to controls, except for low HDL. They were commoner in moderate-severe NAFLD than in intermediate NAFLD. After seven years, the odds of developing new-onset metabolic traits and CVEs were significantly higher compared to controls only in moderate-severe NAFLD.

CONCLUSIONS: Only moderate-severe NAFLD predicted risk of incident adverse MTs and CVEs. However, both moderate-severe and intermediate NAFLD were associated with higher prevalence of adverse anthropometric and metabolic traits, thereby identifying individuals who need medical intervention even among those with milder degrees of fatty liver. We therefore recommend using increased hepatic echogenicity, and not only the more stringent criteria (which include signal attenuation and/or vascular blunting), for the diagnosis of fatty liver in individuals with NAFLD.

来源:Eur J Radiol,查看原文。版权归原作者所有。

引用

  1. Niriella MA, Ediriweera DS, Kasturiratne A, et al. The clinical utility of accurate NAFLD ultrasound grading: Results from a community-based, prospective cohort study. Eur J Radiol. 2021. PMID: 33421884. doi:10.1016/j.ejrad.2020.109516

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。